Why Is ARCUS BIOSCIENCES IN (RCUS) Stock Down Today?

Arcus Biosciences shares fell 19.58% to $19.10 on Tuesday. The sharp decline was driven by the announcement of a $250 million public offering of common stock and the release of kidney-cancer data for casdatifan.

What Happened

The company announced the pricing of a $250 million public offering of common stock, with a price range of $17.50 to $18.50. The offering includes a 30-day underwriter option for up to 15% more shares. This capital raise coincided with the release of data for casdatifan in kidney cancer, which contributed to the sell-off. Additionally, Kuehn Law, PLLC, announced it is investigating whether certain officers and directors of Arcus Biosciences breached their fiduciary duties.

What The Data Shows

The stock printed 81 fresh 52-week lows on October 21, 2026. Over the last eight sessions, the stock moved down 21.5%, falling from $24.34 to $19.10. The 52-week range is $16.35 to $31.73. Fundamentals show a market cap of $2.8 billion, with trailing twelve-month revenue down 55.3% and an EPS of $3.86. The net margin stands at -393.2%. In the last 90 days, there were no insider buys, but one sale totaling $85,000 was recorded, with the most recent filing on August 24, 2026. Alexander Azoy, the Chief Accounting Officer, sold shares on August 21, 2026. Congressional trades show one sale of $1,001 to $15,000 on July 29, 2026, with no buys in the last 90 days.

What To Watch

Investors will monitor the completion of the public offering and any further developments in the shareholder litigation investigation. Analysts from Citigroup and Truist Securities recently maintained Buy ratings, with price targets of $50 and $41, respectively.